Xospata is a prescription drug approved by the Food and Drug Administration (FDA) to treat adults with relapsed or refractory acute myelogenous leukemia (AML) that has tested positive for the FLT3 mutation. Xospata may be referred to by its drug name, Gilteritinib.
Xospata is used as targeted therapy for leukemia. Xospata is a member of a class of drugs called kinase inhibitors. Xospata is believed to work by inhibiting the growth of leukemia cells.
How do I take it?
Prescribing information states that Xospata is taken orally once daily.
Xospata comes in tablet form.
The FDA-approved label for Xospata lists common side effects including fatigue, headache, fever, malaise, dizziness, cough, pneumonia, rash, joint or muscle pain, trouble breathing, low blood pressure, nausea, vomiting, diarrhea, mouth sores, and edema (swelling).
Rare but serious side effects listed for Xospata include pancreatitis, changes in heart rhythm, fetal harm in pregnant women, and posterior reversible encephalopathy syndrome – swelling in the brain that can cause headache, confusion, seizures, and loss of vision.
For more details about this treatment, visit:
Xospata – Astellas
AML: Relapsed and Refractory – Leukemia & Lymphoma Society